BeNeLuxA: Options for an early engagement for orphan drugs and ATMPs
Originally broadcast: Monday 28th September 2020
Duration: 70 minutes. Available to watch on demand
Learning objectives:
You will understand:
What the options are for companies to engage in BeNeLuxA
What the right point to engage is
How scientific advice and horizon scanning are structured
If BeNeLuxA is a “one-stop-shop” for all participating countries or could the company choose the countries to participate
How confidentiality is secured
What the lessons learnt are from previous BeNeLuxA procedures for orphan drugs, cell & gene therapies and companion diagnostics that sometimes accompany such complex treatments
What the future priorities are from the government/payer perspective.
Who would benefit from registering to attend this webinar:
Anyone with commercial, market access or pricing responsibility for Europe or the BeNeLuxA countries, who may be considering efficiencies from joint HTAs rather than submitting to each individual country.
Speakers
Diane Kleinermans, Advisor to the Ministry of Health and Social Affairs Belgium
Please see their LinkedIn page here.
Francis Arickx, Advisor at RIZIV-INAMI
Please see their LinkedIn page here.
Christian Hill, Chief Executive Officer, MAP BioPharma
Christian is a seasoned Market Access professional with over 20 years of experience in the International Biotech and Pharmaceutical industry. He has been involved in over 50 HTAs across Europe and has built up a strong network of key influencers including EU and national agencies. Prior to co-founding MAP in 2012, he led market access teams and submissions at InterMune, Gilead, Pfizer and Genzyme on a very broad range of products and disease areas from chronic disease to ultra-orphan indications.
Christian is a member of the Board of EUCOPE (European Confederation of Pharmaceutical Entrepreneurs); he is also a member of the Steering Group of EMIG (Ethical Medicines Industry Group) in the UK and Ireland.
Dr Alexander Natz, Secretary General, EUCOPE
Alexander Natz is the Secretary General of the European Confederation of Pharmaceutical Entrepreneurs (www.eucope.org) in Brussels and works as a lawyer in the healthcare boutique law firm NOVACOS in Düsseldorf (www.novacos-law.com). He advises innovative pharmaceutical and biotech companies, including start-ups, in regulatory and pricing & reimbursement matters from the EU law and German law perspective.
From 2008 to 2013, he was Head of the Brussels Office of Bundesverband der Pharmazeutischen Industrie eV (BPI). Before, he has been a lawyer at Sträter Law Firm in Germany with a special focus on managed entry agreements and licensing of pharmaceuticals. Dr. Natz has also worked in the field of competition law with the European Commission and in the pharmaceutical industry.
Copyright © 2020. MAP BioPharma Limited. All rights reserved.
MAP BioPharma Limited
Upper Pendrill Court, Ermine Street North
Papworth Everard, Cambridge
Cambridgeshire, CB23 3UY
United Kingdom
+44 (0) 1480 832360
MAP BioPharma Limited is a registered company in England and Wales. Company Registration Number 08209281
VAT Group Registration Number GB 292 8576 52